ETON Eton Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 12:04
Why ETON matters now
Eton Pharmaceuticals, Inc. (ETON) is a US stock in Healthcare. The latest InvestLog snapshot shows $36.15 with -0.07% on the session and $990.1M in market capitalization; recent performance reads 1-month -1.25% and YTD +92.08%.
The latest financial table shown here is Q1 2026, with revenue of $24.3M, net income of $1.6M, and EPS of $0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 1.7%.
The latest indexable market news headline is "Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells Investors" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $57.00; recent insider activity includes Adams Jennifer McKie filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
28.95
P/S
10.23
EV/EBITDA
161.77
DCF Value
$-40.40
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.8%
Operating Margin
2.3%
Net Margin
-1.7%
ROE
-5.7%
ROA
-1.5%
ROIC
3.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $24.3M | $1.6M | $0.05 |
| Q4 2025 | $21.3M | $1.5M | $0.05 |
| FY 2025 | $80.0M | $-4.6M | $-0.17 |
| Q3 2025 | $22.5M | $-1.9M | $-0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$57.00
Target (Median)
$57.00
Target Range
$57.00 - $57.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.89
Eton Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on the invention and market introduction of medical treatments for rare diseases. Its current product lineup features Biorphen and Rezipres, both phenylephrine injections designed to counter significant hypotension arising from vasodilation during anesthesia. The company also offers Carglumic Acid, a treatment for acute and chronic hyperammonemia linked to N-acetylglutamate Synthase deficiency. Further marketed solutions include Alkindi Sprinkle, which serves as a replacement therapy for adrenocortical insufficiency in children younger than 17; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, an ophthalmic product for allergic conjunctivitis that contains no preservatives. Beyond its existing portfolio, Eton is actively developing various pipeline assets. These encompass oral suspensions of Zonisamide and Lamotrigine, both aimed at addressing partial on-set seizures, alongside a cysteine injection, a dehydrated alcohol injection, and the Zeneo hydrocortisone autoinjector. This company was established in 2017 and is headquartered in Deer Park, Illinois.